A recently concluded clinical trial conducted by the National Institutes of Health (NIH) revealed disappointing news: the antiviral drug tecovirimat (TPOXX) has shown no significant improvement in lesion resolution or pain relief for individuals with mild to moderate monkeypox (mpox) cases.
The Study of Tecovirimat for Mpox (STOMP) investigated whether a 14-day course of the drug could accelerate lesion healing and alleviate pain in adults infected with clade II mpox, the strain responsible for the global 2022 outbreak. Participants from various countries, including the US, Brazil, Argentina, and Mexico, took part.
Interim analysis at 75% participant enrollment revealed no difference between the tecovirimat group and the placebo group regarding lesion resolution or pain reduction. Consequently, the Data Safety and Monitoring Board (DSMB) recommended halting further enrollment. Recognizing the findings, the NIH accepted the recommendation and also closed enrollment in an ongoing open-label study group for individuals at higher risk of severe disease, those who received tecovirimat regardless of randomization.
“These findings, while disappointing, offer valuable insights into our search for effective treatments against this evolving threat,” stated Jeanne Marrazzo, MD, MPH, director of NIAID. “There’s no evidence from the STOMP trial to suggest that tecovirimat is effective in treating mild to moderate clade II mpox.”
TPOXX, primarily developed as a smallpox defense, has been investigated as a potential treatment for monkeypox. While the clinical trials, including PALM007 and STOMP, demonstrated the drug’s safety, none showed significant benefits for lessening lesion duration or pain for mild to moderate cases of mpox.
Despite the STOMP results, researchers continue to evaluate tecovirimat for severe mpox cases and individuals with compromised immune systems. The CDC offers extended access to the drug under specific circumstances.
What to Know About Tecovirimat and Mpox Treatments
**Key Takeaways:**
• Tecovirimat, while safe, did not improve lesion healing or pain relief in moderate-to-mild Mpox cases according to new NIH research.
• Tecovirimat remains accessible through specialized CDC programs for eligible individuals, particularly those with severely weakened immune systems.• Ongoing research probes tecovirimat’s potential effectiveness against severe Mpox, especially among immunocompromised patients.
Stay updated on the latest developments with monkeypox and treatment options. Consult reliable sources from organizations like the CDC and WHO for accurate, timely information.
Additional insights are emerging from ongoing clinical trials, including studies happening in the Democratic Republic of Congo, following a recent outbreak of the clade I strain. These studies promise to refine our understanding and treatment strategies for mpox.